

# Resource Summary Report

Generated by RRID on Aug 6, 2026

## Biogen Idec

RRID:SCR\_003790

Type: Tool

---

### Proper Citation

Biogen Idec (RRID:SCR\_003790)

---

### Resource Information

**URL:** [https://www.biogen.com/en\\_us/home.html](https://www.biogen.com/en_us/home.html)

**Proper Citation:** Biogen Idec (RRID:SCR\_003790)

**Description:** Global biotechnology company based in Cambridge, Massachusetts, specializing in discovering, developing, and delivering important therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases to patients worldwide.

**Abbreviations:** BIIB

**Synonyms:** Biogen Idec Inc.

**Resource Type:** commercial organization

**Keywords:** drug, biotechnology

**Related Condition:** Neurodegenerative disease, Hematologic disease, Autoimmune disease, Multiple Sclerosis, Hemophilia

**Resource Name:** Biogen Idec

**Resource ID:** SCR\_003790

**Alternate IDs:** nlx\_158083

**Old URLs:** <http://www.biogenidec.com/>

**Record Creation Time:** 20220129T080220+0000

**Record Last Update:** 20260801T190219+0000

---

### Ratings and Alerts

No rating or validation information has been found for Biogen Idec.

No alerts have been found for Biogen Idec.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 564 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#).

Lovett A, et al. (2025) Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis. *Muscle & nerve*, 71(6), 1006.

Grillo P, et al. (2025) Amplification parameters of the alpha-synuclein seed amplification assay on CSF predict the clinical subtype of Parkinson's Disease at 10-year follow-up. *medRxiv : the preprint server for health sciences*.

Phadke RA, et al. (2025) The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking. *Molecular psychiatry*, 30(2), 796.

Yang W, et al. (2025) From Lab to Clinic: Effect of Academia-Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry. *Clinical and translational science*, 18(1), e70135.

Chaves B, et al. (2025) In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis. *Nature communications*, 16(1), 5533.

Lynch JP, et al. (2025) Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis. *mAbs*, 17(1), 2505090.

Yousuf MS, et al. (2025) Diroximel Fumarate Acts Through Nrf2 to Attenuate Methylglyoxal-Induced Nociception in Mice and Decrease ISR Activation in DRG Neurons. *Diabetes*, 74(5), 827.

Jiang D, et al. (2025) Quantitative Determination of Click-Reactive Antisense Oligonucleotide and Its Reactivity in Rat Brains by Hybridization LC-MS/MS to Support Pretargeted PET Imaging. *Analytical chemistry*, 97(23), 12155.

de Sèze J, et al. (2025) LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France. *Advances in therapy*, 42(4), 1760.

Van Zyl M, et al. (2025) Brain-Death in Rats Increases Neutrophil Extracellular Trap Formation in Donor Organs. *Transplant international : official journal of the European Society for Organ Transplantation*, 38, 14223.

Butler PM, et al. (2025) Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment. *Nature medicine*, 31(3), 829.

Filippi M, et al. (2025) Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project. *Journal of neurology*, 272(1), 96.

Sato K, et al. (2025) Sentiment analysis of social media responses to the approval of lecanemab for the treatment of Alzheimer's disease in Japan. *Journal of Alzheimer's disease reports*, 9, 25424823241307639.

Droby A, et al. (2025) Radiological markers of CSF  $\alpha$ -synuclein aggregation in Parkinson's disease patients. *NPJ Parkinson's disease*, 11(1), 7.

Bast N, et al. (2025) Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry. *The Lancet regional health. Europe*, 48, 101137.

Ferro A, et al. (2024) The cytokine receptor Fn14 is a molecular brake on neuronal activity that mediates circadian function in vivo. *bioRxiv : the preprint server for biology*.

Jiang D, et al. (2024) Bioanalysis of free antisense oligonucleotide payload from antibody-oligonucleotide conjugate by hybridization LC-MS/MS. *Bioanalysis*, 16(15), 791.

Clausen L, et al. (2024) A mutational atlas for Parkin proteostasis. *Nature communications*, 15(1), 1541.

Chen S, et al. (2024) Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade. *Journal of translational medicine*, 22(1), 241.

Chen Q, et al. (2024) LT $\beta$ R-RelB signaling in intestinal epithelial cells protects from chemotherapy-induced mucosal damage. *Frontiers in immunology*, 15, 1388496.